Table 1 Clinicopathological information of the patients included in this study according to the TERT promoter genotype.
TERT promoter genotype | ||
|---|---|---|
wild-type | mutated | |
Cases studied (n, %) | 51 (93%) | 4 (7%) |
Age (range) | 54 (14–75) | 44 (32–55) |
Location (n, %) | ||
Head | 23 (45%) | — |
Body | 7 (14%) | 2 (50%) |
Tail | 20 (39%) | 2 (50%) |
n.d. | 1 (2%) | — |
Grade (n, %) | ||
G1 | 35 (69%) | 2 (50%) |
G2 | 14 (27%) | 2 (50%) |
G3 | 2 (4%) | — |
pT stage (ENETS) (n, %) | ||
T1 | 16 (31%) | — |
T2 | 20 (39%) | 2 (50%) |
T3 | 12 (24%) | 2 (50%) |
T4 | 3 (6%) | — |
pT stage (UICC/AJCC) (n, %) | ||
T1 | 18 (35%) | — |
T2 | 18 (35%) | 1 (25%) |
T3 | 15 (30%) | 3 (75%) |
T4 | — | — |
Lymph node metastasis (n, %) | 17 out of 31 (55%) | 3 (75%) |
Distant metastasis (n, %) | 5 (10%)1 | 1 (25%)2 |
Hereditary syndrome association | — | 3 (75%)3 |
